

SM.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/799,910	02/13/1997	DEAN A. FALB	7853-067	4373

7590 03/10/2004

PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 10036

EXAMINER

NGUYEN, DAVE TRONG

ART UNIT	PAPER NUMBER
----------	--------------

1632

DATE MAILED: 03/10/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

S.M.

Office Action Summary**Application No.**

08/799,910

Applicant(s)

FALB, DEAN A.

Examiner

Dave T. Nguyen

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 02 December 2003.
 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 103-117 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) ☒ Claim(s) 104 is/are allowed.
 6) ☒ Claim(s) 103 and 105-117 is/are rejected.
 7) ☐ Claim(s) _____ is/are objected to.
 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some * c) ☐ None of:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
 * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____.
 4) ☐ Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____.
 5) ☐ Notice of Informal Patent Application (PTO-152)
 6) ☐ Other: _____.

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 17, 2002 has been entered.

Claims 108-115 have been amended by the amendment filed August 9, 2001.

Claims 103-117, to which the following grounds of rejection are applicable, are pending.

A review of the as-filed specification discovers that SEQ ID NO: 10 only consists 156 amino acid residues. However, all of the presently pending claims have been amended incorrectly by referring to "at least amino acids 71-157 of the fchd605 polypeptide depicted in SEQ ID NO: 10". Thus, the claims are objected because of an appearance of a typographical error. Correction is requested.

The specification is also objected to under 37CFR 1.52(b), which requires that the pages of the specification be numbered starting with "1". Pages i-iv of the specification do not conform with the arrangement of the specification according to MPEP 608.01(a), particularly since the item (b) "Cross Reference to Related Applications" does not appear on the first paragraph of the specification, and since the title headings appear both at page i and page 1 of the specification. It is suggested that pages i-iv should be deleted or removed from the specification. Should applicant

intends to keep pages I-vi as part of the specification, Applicant must amend the specification to delete any reference to page numbers since a patent if issued from the as-filed application is not arranged by page numbering but by column numbering.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. § 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 103, 105-117 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention encompassing any and/or all polynucleotide sequences including coding regions, introns, 5' and 5' regulatory elements, other untranslated regions, full length ORFs, structurally unrelated DNA sequences, and partial DNA sequences of genes other than nucleotides 211-468 of SEQ ID NO: 9.

The claims encompass a genus of "polynucleotide sequences" comprising nucleotides corresponding to coding regions, introns, 5' and 3' regulatory elements, and untranslated regions of the genes, full-length encoded cDNA and/or genes (claim 103),

Art Unit: 1632

and structurally unrelated DNAs, and partial DNA sequences of genes other than nucleotides 211-468 of SEQ ID NO: 9 (claim 103, and claim 105).

Essentially, the presently claimed invention with respect to a genus of isolated nucleotide sequences, each of which comprising at least nucleotide 211-468 of SEQ ID NO: 9, does not appear to have sufficient description of the claimed isolated nucleotide sequences, particularly since the as-filed specification only describes "a partial open reading frame of approximately 258 bp, encoding approximately 86 amino acid" (first par. of page 118), *e.g.*, nucleotides 211-468 of SEQ ID NO: 9, which encodes amino acid 71-156 of SEQ ID NO: 10, wherein the partial open reading frame was only described at the time of filing as being portion of "a 1.5kb mRNA that is upregulated after 5 hours treatment with oxidized LDL, and to a lesser degree with native LDL, as compared to untreated monocytes" (see page 118, first par.).

An adequate written description of the invention defined by the claims, *e.g.* genus of polynucleotide sequences and/or genes and/or unrelated DNA sequences that hybridize to nucleotides 211-468 of SEQ ID NO: 9, requires more than a mere statement that it is part of the invention and reference to a knowledge in the art as to a partial open reading frame (ORF) as set forth in SEQ ID NO: 9; what is required is the knowledge in the prior art and/or a description as to the availability of a representative number of species of the claimed genus. The specification describes an isolated cDNA fragment (nucleotides 211-468 of SEQ ID NO: 9) obtained from a human endothelial cell library which was induced under shear stress conditions. Nucleotides 211-468 of SEQ ID NO: 9 is asserted to be homologous to the mouse gly96 cDNA, which encodes

Art Unit: 1632

a cytokine inducible glycosylated protein expressed in mouse lung, tested, and uterus. Further, the specification indicates that it would be reasonable to infer that the partial sequence of nucleotides 211-468 of SEQ ID NO: 9 can be used as a probe to isolate the mouse gly96 cDNA. A search of prior art indicates that nucleotides 211-468 of SEQ ID NO: 9 as of Feb. 16, 1996 is novel and unobvious and no associated genomic clones have been identified, and that other than the mouse gly96 cDNA, no other unrelated cDNA sequences has greater than 50% similarity to the disclosed nucleotides. A review of the specification indicates that elements, including coding regions, introns, 3' and 5' regulatory elements, other untranslated regions, full length ORFs, structurally unrelated DNAs, and partial DNA sequences of genes other than nucleotides 211-468 of SEQ ID NO: 9, are not particularly described in a specific sequence structure that could be envisioned by a skilled artisan at the time of filing. There is no actual reduction to practice the full scope of the claimed invention, clear depiction of the claimed invention in the drawings or complete detailed description of the structure. Considering all disclosed distinguishing identifying characteristics, there is a disclosure of only nucleotides 211-468 of SEQ ID NO: 9 as well as the function of the nucleotides as a probe for subjects having monocytes undergoing conditions of oxidized LDL treatment.

In other words, there is no known or disclosed correlation between this function and the structure of the non-described coding regions, introns, 3' and 5' regulatory elements, other untranslated regions, full length ORFs, structurally unrelated DNAs, and partial DNA sequences of genes other than nucleotides 211-468 of SEQ ID NO: 9. Furthermore, there is no additional disclosure of physical and/or chemical properties.

Weighing all factors in view of the level of knowledge and skill in the art, one skilled in the art would not recognize from the disclosure that applicant was in possession of the genus which comprises *per se* a representative number of nucleotide sequences, which may comprise at least nucleotides 211-468 of SEQ ID NO: 9. Note that claiming a full-length coding sequence, gene, regulatory sequences, and unrelated cDNA sequences that achieve a result without defining what means will do so is not in compliance with the written description requirement. Rather, it is an attempt to preempt the future before it has arrived. (See *Fiers v. Revel*, 25 USPQ2d 1601 (CA FC 1993) and *Regents of the Univ. Calif. v. Eli Lilly & Co.*, 43 USPQ2d 1398 (CA FC, 1997)). In view of the reasons set forth above, one skilled in the art at the time the invention was made would not have recognized that applicant was in possession of the claimed genus other than a DNA sequence consisting of nucleotides 211-468 of SEQ ID No: 9.

Claims 103, and 105-117 are also rejected under 35 U.S.C. 112, first paragraph because the specification is only enabling for claimed invention as recited in claim 104. The specification is not enabling for the claimed subject matter being sought in claim 103, and claims dependent therefrom.

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Specifically, since the claimed invention is not supported by a sufficient written description (for possessing of the genus of polynucleotide sequences as recited in the

Art Unit: 1632

claims) for the reasons set forth above, one skilled in the art would not know how to use and make the claimed invention so that it would operate as intended without undue experimentation.

Previous Applicant's responses have been considered fully by the examiner but the responses are not found persuasive because of the specific issues as set forth in the above stated rejections. The responses do not in any way address fully to the lack of the written description to the full breadth of the claimed invention.

Claim 104 is allowable because the prior art of record does not teach or suggest the polynucleotide as recited in the claim.

Claims 106-117 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of claim 104 and any intervening claims.

No claims are allowed.

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner *Dave Nguyen* whose telephone number is **(571-272-0731)**.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *Amy Nelson* may be reached at **571-272-0184**

Any inquiry of a general nature or relating to the status of this application should be directed to the *Group receptionist* whose telephone number is **(703) 308-0196**.

Dave Trong Nguyen
Primary Examiner
Art Unit: 1632



DAVE T. NGUYEN
PRIMARY EXAMINER